Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

被引：0
|
作者：
S J Isakoff
D Wang
M Campone
A Calles
E Leip
K Turnbull
N Bardy-Bouxin
L Duvillié
E Calvo
机构：
[1] Massachusetts General Hospital Cancer Center,Division of Hematology and Oncology
[2] and Harvard Medical School,undefined
[3] Phase I Clinical Trials Program,undefined
[4] Henry Ford Hospital,undefined
[5] 2799 West Grand Boulevard,undefined
[6] Institut de Cancerologie de l'Quest—Rene Gauducheau,undefined
[7] Saint Herblain,undefined
[8] START Madrid,undefined
[9] Centro Integral Oncológico Clara Campal,undefined
[10] Hospital Madrid Norte-Sanchinarro,undefined
[11] Oncology Clinical Statistics,undefined
[12] Pfizer Inc,undefined
[13] Oncology Clinical Development,undefined
[14] Pfizer Inc,undefined
[15] 10 Fawcett Street,undefined
[16] Suite 2013,undefined
[17] Oncology Late Phase Strategy Development,undefined
[18] Pfizer Global Research and Development,undefined
[19] Oncology Clinical Development,undefined
[20] Pfizer Global Research and Development,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
bosutinib; capecitabine; neoplasms; metastatic cancer; phase 1; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2058 / 2066
页数：8
相关论文
共 50 条
  • [31] A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
    Juric, Dejan
    Soria, Jean-Charles
    Sharma, Sunil
    Banerji, Udai
    Azaro, Analia
    Desai, Jayesh
    Ringeisen, Francois Philippe
    Kaag, Audrey
    Radhakrishnan, Rajkumar
    Hourcade-Potelleret, Florence
    Maacke, Heiko
    Ahnert, Jordi Rodon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deeps Suresh
    Hurwitz, Herbert
    Kang, Yoon-Koo
    Kim, Tae-You
    Shepherd, Stacie Peacock
    Xiong, Hao
    Hetman, Robert
    Nickner, Caroline
    Dudley, Matthew W.
    Giranda, Vincent L.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
    Normand Blais
    D. Ross Camidge
    Derek J. Jonker
    Denis Soulières
    Scott A. Laurie
    Sami G. Diab
    Ana Ruiz-Garcia
    Aron Thall
    Ke Zhang
    Richard C. Chao
    Laura Q. Chow
    Investigational New Drugs, 2013, 31 : 1487 - 1498
  • [34] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [35] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
    Wu, Y.
    Jing, H.
    Zhang, J.
    Cao, X.
    Li, K.
    Liu, Y.
    Meng, M.
    Li, H.
    Kang, W.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
  • [36] A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
    Ferrarotto, R.
    Eckhardt, G.
    Patnaik, A.
    LoRusso, P.
    Faoro, L.
    Heymach, J. V.
    Kapoun, A. M.
    Xu, L.
    Munster, P.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1561 - 1568
  • [37] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [38] Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
    Takashi Seto
    Taito Esaki
    Fumihiko Hirai
    Shuji Arita
    Kaname Nosaki
    Akitaka Makiyama
    Takuro Kometani
    Chinatsu Fujimoto
    Motoharu Hamatake
    Hiroaki Takeoka
    Felix Agbo
    Xiaojin Shi
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 619 - 627
  • [39] Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
    Seto, Takashi
    Esaki, Taito
    Hirai, Fumihiko
    Arita, Shuji
    Nosaki, Kaname
    Makiyama, Akitaka
    Kometani, Takuro
    Fujimoto, Chinatsu
    Hamatake, Motoharu
    Takeoka, Hiroaki
    Agbo, Felix
    Shi, Xiaojin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 619 - 627
  • [40] Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
    Li, H.
    Xu, J.
    Shao, B.
    Liu, R.
    Ran, R.
    Song, G.
    Jiang, H.
    Wang, K.
    Shi, Y.
    Liu, J.
    Hu, W.
    Chen, F.
    Zhang, G.
    Wang, Y.
    Zhao, C.
    Ru, J.
    Wang, Q.
    Rugo, H. S.
    Li, G.
    ANNALS OF ONCOLOGY, 2019, 30
12345